Subtopic Deep Dive
Minimal Residual Disease in ALL
Research Guide
What is Minimal Residual Disease in ALL?
Minimal Residual Disease (MRD) in Acute Lymphoblastic Leukemia (ALL) refers to the small number of leukemic cells persisting after treatment, detected by sensitive methods like flow cytometry and quantitative PCR to predict relapse risk.
MRD assessment guides risk-stratified therapy in childhood ALL patients. Flow cytometry and real-time quantitative RT-PCR detect MRD levels post-induction. Borowitz et al. (2008) demonstrated MRD's prognostic superiority over other factors in Children's Oncology Group trials (826 citations).
Why It Matters
MRD directs treatment intensification, reducing relapse in high-MRD cases and sparing low-MRD patients from toxicity (Borowitz et al., 2008). Pui et al. (2009) omitted cranial irradiation using MRD for risk adaptation, improving survival without added toxicity (1204 citations). Hunger et al. (2012) linked MRD-based protocols to survival gains from 1990-2005 in COG trials (1168 citations). Terwilliger and Abdul-Hay (2017) highlighted MRD's role in modern ALL management (1228 citations).
Key Research Challenges
MRD Detection Sensitivity
Achieving consistent detection limits below 0.01% remains challenging across labs using flow cytometry or PCR. Gäbert et al. (2003) standardized real-time qRT-PCR for fusion transcripts but noted variability in leukemia subtypes (1515 citations). Inter-lab quality control limits reproducibility.
Prognostic Integration
Combining MRD with genetics like IKZF1 deletions for risk models is complex. Mullighan et al. (2009) showed IKZF1 alterations predict poor outcome independent of MRD (1420 citations). Borowitz et al. (2008) found MRD refines but does not replace cytogenetics.
Relapse Prediction Accuracy
MRD fails to predict all relapses, especially in Ph-like ALL. Roberts et al. (2014) identified kinase lesions in Ph-like ALL with high relapse despite MRD monitoring (1347 citations). Timing and threshold optimization need refinement per patient age.
Essential Papers
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
David Grimwade, Robert K. Hills, Anthony V. Moorman et al. · 2010 · Blood · 1.9K citations
Abstract Diagnostic karyotype provides the framework for risk-stratification schemes in acute myeloid leukemia (AML); however, the prognostic significance of many rare recurring cytogenetic abnorma...
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis
Christian Thiede, Christine Steudel, Brigitte Mohr et al. · 2002 · Blood · 1.7K citations
Constitutive activation of the FLT3 receptor tyrosine kinase, either by internal tandem duplication (ITD) of the juxtamembrane region or by point mutations in the second tyrosine kinase domain (TKD...
Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program
J Gäbert, Emmanuel Beillard, Vincent H. J. van der Velden et al. · 2003 · Leukemia · 1.5K citations
Deletion of <i>IKZF1</i> and Prognosis in Acute Lymphoblastic Leukemia
Charles G. Mullighan, Xiaoping Su, Jinghui Zhang et al. · 2009 · New England Journal of Medicine · 1.4K citations
Genetic alteration of IKZF1 is associated with a very poor outcome in B-cell-progenitor ALL.
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
Kathryn G. Roberts, Yongjin Li, Debbie Payne-Turner et al. · 2014 · New England Journal of Medicine · 1.3K citations
Ph-like ALL was found to be characterized by a range of genomic alterations that activate a limited number of signaling pathways, all of which may be amenable to inhibition with approved tyrosine k...
Acute lymphoblastic leukemia: a comprehensive review and 2017 update
T Terwilliger, Maher Abdul‐Hay · 2017 · Blood Cancer Journal · 1.2K citations
Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation
Ching-Hon Pui, Dario Campana, Deqing Pei et al. · 2009 · New England Journal of Medicine · 1.2K citations
With effective risk-adjusted chemotherapy, prophylactic cranial irradiation can be safely omitted from the treatment of childhood ALL. (ClinicalTrials.gov number, NCT00137111.)
Reading Guide
Foundational Papers
Start with Borowitz et al. (2008) for MRD's clinical significance in COG trials (826 citations), then Gäbert et al. (2003) for qPCR standardization (1515 citations), followed by Pui et al. (2009) on risk-adapted therapy without irradiation.
Recent Advances
Terwilliger and Abdul-Hay (2017) review ALL updates including MRD (1228 citations); Roberts et al. (2014) on Ph-like lesions challenging MRD predictions (1347 citations).
Core Methods
Flow cytometry for immunophenotypic MRD (Borowitz et al., 2008); real-time qRT-PCR for fusion transcripts (Gäbert et al., 2003); risk models combining MRD with IKZF1 status (Mullighan et al., 2009).
How PapersFlow Helps You Research Minimal Residual Disease in ALL
Discover & Search
Research Agent uses searchPapers and exaSearch to find MRD literature, revealing Borowitz et al. (2008) as a cornerstone with 826 citations on MRD's prognostic role in COG studies. citationGraph traces connections from Gäbert et al. (2003) standardization efforts to modern protocols. findSimilarPapers expands from Pui et al. (2009) to irradiation-free regimens.
Analyze & Verify
Analysis Agent applies readPaperContent to extract MRD thresholds from Borowitz et al. (2008), then verifyResponse with CoVe checks claims against Hunger et al. (2012) survival data. runPythonAnalysis computes relapse rates from COG trial tables using pandas, with GRADE grading MRD evidence as high-quality. Statistical verification confirms MRD's independence from cytogenetics.
Synthesize & Write
Synthesis Agent detects gaps in MRD-Ph-like ALL integration from Roberts et al. (2014), flagging contradictions with Mullighan et al. (2009). Writing Agent uses latexEditText and latexSyncCitations to draft risk-stratification reviews, latexCompile for figures, and exportMermaid for protocol flowcharts.
Use Cases
"Run survival analysis on MRD levels from COG trials in Borowitz 2008"
Analysis Agent → readPaperContent (Borowitz et al., 2008) → runPythonAnalysis (pandas survival curves on MRD data) → matplotlib plot of hazard ratios.
"Generate LaTeX review of MRD protocols in childhood ALL"
Synthesis Agent → gap detection (Pui 2009 + Hunger 2012) → Writing Agent → latexEditText (draft) → latexSyncCitations (add Borowitz) → latexCompile (PDF output).
"Find code for qPCR MRD analysis from Gäbert 2003 papers"
Research Agent → searchPapers (Gäbert et al., 2003) → paperExtractUrls → paperFindGithubRepo → githubRepoInspect (qRT-PCR pipelines for fusion transcripts).
Automated Workflows
Deep Research workflow scans 50+ ALL papers via searchPapers, structures MRD reports with Borowitz et al. (2008) as anchor, outputs GRADE-scored summaries. DeepScan's 7-step chain verifies MRD claims from Gäbert et al. (2003) with CoVe checkpoints and runPythonAnalysis on standardization data. Theorizer generates hypotheses linking IKZF1 deletions (Mullighan et al., 2009) to MRD thresholds.
Frequently Asked Questions
What is Minimal Residual Disease in ALL?
MRD measures leukemic cells post-treatment via flow cytometry or PCR, predicting relapse (Borowitz et al., 2008).
What are main MRD detection methods?
Real-time qRT-PCR for fusion transcripts (Gäbert et al., 2003) and flow cytometry; standardization improves consistency (1515 citations).
What are key MRD papers?
Borowitz et al. (2008, Blood, 826 citations) on prognostic significance; Pui et al. (2009, NEJM) on therapy adaptation.
What are open problems in MRD research?
Integrating MRD with Ph-like genetics (Roberts et al., 2014); refining thresholds for adolescents; lab standardization gaps.
Research Acute Lymphoblastic Leukemia research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Minimal Residual Disease in ALL with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers